City Maintains Buy Rating On Medco Health Solutions

According to Citi, Medco Health Solutions (NYSE: MHS) Buy rating is maintained.

Citi said that it recently attended the Drug Information Association (DIA) annual conference in Chicago and visited with the United BioSource (UBC) segment of Medco. “We maintain our Buy rating on MHS shares given the attractive valuation, but suspect that share upside could be limited in the near-term as we see few positive catalysts in the near term that would outweigh the United Health contract.”

Medco Health Solutions closed yesterday at $54.81.